Opinion editor's note: Editorials represent the opinions of the Star Tribune Editorial Board, which operates independently from the newsroom.
•••
Amelia Helm's twins had just turned 1 when the COVID-19 pandemic began. Now they're 3, and the Richfield family is still waiting for the little boys' chance to get the most potent protection medicine offers against the virus — the COVID vaccine.
Kids under 5 are the last group for which the shots have been authorized for general use. For families like the Helms, that has meant keeping their guard up against COVID long after others who were vaccinated eased up and returned to a more normal life.
Finally, the twins' turn appears to be close at hand, with U.S. Food and Drug Administration (FDA) advisers on Thursday greenlighting the Pfizer and Moderna shots for kids down to six months of age. That should swiftly clear the way for other regulatory signoffs needed. The vaccines could be available as early as next week.
Helm is already planning to get her sons immunized expeditiously. The shots will protect her kids. She also hopes their availability will cut down on the child care disruption created by even a single case of COVID in her sons' preschool classroom, which triggers a five-day quarantine and follow-up testing for exposed kids.
"I'm excited about one less serious illness that kids are going to come down with in the scope of all the germs and viruses they are exposed to," Helm told an editorial writer.
Hopefully, peace of mind will spur parents in Minnesota and elsewhere to get their kids the shots, too. But COVID vaccine uptake in older kids suggests that innovative strategies are critical to boost awareness of the vaccines' new availability and help parents find a place to get the no-cost shots.